![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
The objective of this study was to assess adherence of HIV-1-infected patients who started treatment in the pre-HAART era and to determine variables associated with better adherence, including relevant attitudes and beliefs. This is a cross-sectional study enrolling patients who had received antiretroviral therapy for ≥10 years. Adherence was evaluated through self-reporting and plasma drug concentrations. Treatment variables, attitudes and beliefs were collected during structured interviews. The results show that for 87 patients the median (interquartile range) time on therapy was 13 (10–19) years; 80 were on therapy at the time of analysis. Adherence was ≥95% in 54 patients (67.5%), 90–94% in 22 (27.5%) and <90% in 4 (5%). Drug concentrations were below the lower limit of detection in five patients. Younger age (p=0.014), female gender (p=0.005), current substance abuse (p=0.004) and hepatitis C virus co-infection (p<0.001) were related to lower adherence. Adherence did not differ in relation to different drug families or once- or twice-daily regimens. Patients with adherence <95% were more likely to have interrupted treatment without doctor's recommendation (p=0.009). Adherent patients exhibited a higher perception of risk of developing the illness and of benefits of therapy, higher self-efficacy and intention to adhere and were more influenced by events that motivate medication intake. To conclude, adherence was >90% in most patients on antiretroviral therapy for ≥10 years. Adherence was more related to beliefs about health and illness than to the characteristics of medication or level of knowledge about treatment. Care adherence interventions should include assessment of health beliefs.
This work was presented in part at the 10th European AIDS Conference/EACS, Dublin, Ireland, 17 to 20 November 2005, abstr. Pe10.1/2 and at the 8th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, 13 to 16 November 2006, abstr. P171.
This work was presented in part at the 10th European AIDS Conference/EACS, Dublin, Ireland, 17 to 20 November 2005, abstr. Pe10.1/2 and at the 8th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, 13 to 16 November 2006, abstr. P171.
Notes
This work was presented in part at the 10th European AIDS Conference/EACS, Dublin, Ireland, 17 to 20 November 2005, abstr. Pe10.1/2 and at the 8th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, 13 to 16 November 2006, abstr. P171.